PD-L1–High Tumors Medical Services in China

PD-L1 high-expression tumors refer to malignancies—such as non-small cell lung cancer (NSCLC), melanoma, urothelial carcinoma, and certain head and neck cancers—in which tumor cells or immune infiltrates exhibit elevated programmed death-ligand 1 (PD-L1) protein expression, typically quantified via immunohistochemistry (IHC) assays (e.g., TPS ≥50% or CPS ≥10). This biomarker signifies an adaptive immune resistance mechanism: PD-L1 binding to PD-1 on cytotoxic T lymphocytes inhibits antitumor immunity. Consequently, PD-L1 status serves as a predictive biomarker for response to immune checkpoint inhibitors (ICIs), particularly anti-PD-1/PD-L1 monoclonal antibodies like pembrolizumab, nivolumab, and sintilimab. While not all PD-L1–high tumors respond uniformly—due to tumor heterogeneity, dynamic expression, and coexisting immunosuppressive factors—patients with high PD-L1 expression generally demonstrate improved objective response rates, progression-free survival, and overall survival following ICI monotherapy or combination regimens.

China offers distinct advantages for international patients seeking PD-L1–guided immunotherapy. Leading oncology centers—including Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center—maintain NMPA-approved companion diagnostics, FDA/EMA-aligned IHC protocols, and extensive clinical trial experience with both global and domestically developed ICIs (e.g., sintilimab, camrelizumab). Advanced PET-CT, digital pathology platforms, and real-time molecular tumor boards ensure precise patient stratification. Success rates align with international benchmarks: in first-line NSCLC with PD-L1 TPS ≥50%, 2-year OS exceeds 60% with pembrolizumab or sintilimab. Crucially, treatment costs are 40–60% lower than in the US or Western Europe—with transparent, all-inclusive pricing covering diagnostics, therapy, nursing, and follow-up—without compromising quality or regulatory rigor. As a dedicated medical tourism agency, we facilitate seamless access: coordinating appointments with certified oncologists, verifying PD-L1 testing methodology, arranging visa support and accommodation, and providing bilingual care coordination from initial consultation through post-treatment monitoring—ensuring clarity, continuity, and confidence throughout the therapeutic journey.

Medical Travel to China Guide: PD-L1-High Expressing Tumors (Oncology)

Patients traveling to China for PD-L1-high expressing tumor treatment must obtain a Medical Visa (Q2 or X1, depending on duration), supported by an invitation letter from the treating hospital and a confirmed treatment plan. We assist with visa documentation, embassy coordination, and translation of medical records. Regarding payment, China does not accept most international health insurance; however, our agency provides transparent, all-inclusive pricing—covering consultations, biomarker testing (IHC/NGS), immunotherapy (e.g., pembrolizumab or sintilimab), and hospital fees—quoted upfront in USD/EUR with no hidden costs. We facilitate secure wire transfers or credit card payments directly to accredited hospitals. Accommodation is arranged near partner oncology centers (e.g., PUMCH, Fudan University Cancer Center), with options ranging from serviced apartments to hospital-adjacent hotels; companions are welcome and accommodated at preferential rates. Post-treatment, our dedicated care coordinators provide 6 months of remote follow-up: scheduling virtual oncologist check-ins, interpreting lab/imaging reports, coordinating local lab work abroad, and assisting with therapy adjustments or second opinions—all included in your package. We ensure continuity of care long after you return home.